Yan X, et al. - Researchers investigated the influence of administering first-line treatment with epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) in combination with chemotherapy on the prognosis of patients with advanced non-small cell lung cancer (NSCLC) who harbor low-abundance EGFR mutations. Seventy-six patients with advanced NSCLC who harbored low-abundance EGFR mutations received either EGFR-TKI combined with a platinum-based regimen (combination group) or EGFR-TKI therapy (monotherapy group). Outcomes revealed significantly improved PFS and OS in correlation with first-line treatment with EGFR-TKI plus chemotherapy in patients with advanced NSCLC and low-abundance EGFR mutations. Adverse reactions were encountered more frequently in the combination group, but all the adverse reactions were expected and tolerated.